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To determine the role of regulatory T lymphocytes (Tregs) in the pathogenesis of human chronic graft-versus-
host disease (GVHD) and its clinical resolution, we evaluated long-term recipients of pediatric allogeneic
hematopoietic stem cell transplantation (HSCT). Seventy-one recipients were evaluated, 30 of whom had a
history of chronic GVHD, including 16 with active chronic GVHD and 14 with resolved chronic GVHD. There
were no signiﬁcant clinical differences and no differences in the frequency of Tregs (CD4þ, CD127, CD25þ)
between the recipients with active chronic GVHD and those with resolved chronic GVHD. Using the Miyara/
Sakaguchi classiﬁcation scheme to identify functional Tregs, a decreased frequency of functional resting Tregs
(rTregs) was identiﬁed in recipients with active chronic GVHD (P ¼ .009 compared with normal donors;
P ¼ .001 compared with HSCT recipients without history of chronic GVHD; P ¼ .005 compared with recipients
with resolved chronic GVHD). The frequency and number of recent thymic emigrants in rTregs were normal
in recipients with resolved chronic GVHD, but persistently decreased in recipients with active chronic GVHD.
These results support the hypothesis that the reestablishment of normal numbers of functional rTregs is
required for the clinical resolution of chronic GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Given the clinical similarity of chronic graft-versus-host
disease (GVHD) to systemic sclerosis and other autoimmune
diseases in humans, the idea that the pathogenesis of chronic
GVHD differs from that of acute GVHD has been debated for
many years [1-3]. It is clear that donor-derived T lymphocytes
with speciﬁcity for recipient-restricted histocompatibility
antigens and the associated cytokines are responsible for the
development of acute GVHD; however, the pathogenesis of
chronic GVHD is less clear, with recent research focusing on
the role of regulatory T lymphocytes (Tregs).
Clinical research into chronic GVHD has been confounded
by ambiguities in the deﬁnition of human Tregs. In most
previous studies, Tregs were immunophenotypically identi-
ﬁed by phenotype: CD4þ, CD127, CD25þ (Figure 1A); how-
ever, in contrast tomice, inwhich all functional Tregs expressedgments on page 1515.
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expressing human Tregs are functional [4-6]. Miyara et al. [7]
developed a classiﬁcation of human Tregs that permits the
immunophenotypic identiﬁcation and quantitation of func-
tional human Tregs. Two functional Treg subpopulations are
identiﬁed: resting Tregs (rTregs), representing 20% of the
total Tregs in normal individuals and their activated progeny,
activated Tregs (aTregs), which represent 5% (Figure 1A).
Thus, only 25% of Tregs (CD4þ, CD127, CD25þ) have a reg-
ulatory function in humans.
We have used the Miyara/Sakaguchi classiﬁcation
of functional human Tregs to quantify the frequency and
number of rTregs and aTregs in the long-term pediatric
recipients of hematopoietic stem cell transplantation (HSCT).
The purpose of the present study was to examine the role of
functional Tregs in the development of human chronic GVHD
and the clinical resolution of chronic GVHD. Many HSCT
recipients with chronic GVHD experience clinical resolution
of chronic GVHD after ﬁrst-line (50% clinical resolution rate)
or second-line (15% clinical resolution rate) immunosup-
pressive therapy, with the ultimate discontinuation of
immunosuppression [8,9]. Although the clinical factors that
increase the risk of developing chronic GVHD have been
identiﬁed (eg, previous acute GVHD, older recipient age,
use of mobilized peripheral blood stem cells, total bodyTransplantation.
Figure 1. (A) Schema for immunophenotypic analyses of CD4 T lymphocytes, Tcons (CD4þ, CD127þ, CD25), and Tregs (CD4þ, CD127, CD25þ) from an HSCT recipient
with active cGVHD. (I) FoxP3 staining of Tcons. (II) control IgG staining of Tregs. (III) Fox P3 staining of Tregs with identiﬁcation of rTregs (CD4þ, CD127, CD25þ,
CD45RAþ, FoxP3þ; P12), aTregs (CD4þ, CD127, CD25þ, CD45RA, FoxP3þþþ; P9), and subpopulation A (A: CD4þ, CD127, CD25þ, CD45RAþ, FoxP3; Q1-1). (B)
Immunophenotypic detection of RTEs (CD4þ, CD45RAþ, CD31þ) in the rTregs (P12).
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histocompatible donors), the biological basis for the clinical
resolution of chronic GVHD has not been investigated.
Our study is the ﬁrst to demonstrate that HSCT recipients
with active chronic GVHD have markedly lower than normal
frequency and number of functional rTregs, whereas HSCT
recipients with clinical resolution of chronic GVHD have
normal values. To better understand the basis for the
normalization of rTregs in the recipients with resolved
chronic GVHD, we investigated the contribution of the
thymus to the rTregs in recipients with active and resolved
chronic GVHD by measuring the frequency of recent thymic
emigrants (RTEs) within the rTreg subpopulation. Whereas
the recipients with active chronic GVHD exhibited sustaineddecreases in the frequency and numbers of RTEs within their
rTregs, those with resolved chronic GVHD demonstrated an
initial increase in the frequency of RTEs within their rTreg
subpopulation, which normalized over time. Overall, our
results suggest that the immunologic resolution of human
chronic GVHD is related to the reestablishment of normal
immune regulation secondary to the improved thymic pro-
duction of functional Tregs.
PATIENTS AND METHODS
Patients
This nonselected cross-sectional evaluation of allogeneic HSCT re-
cipients was conducted between March 2011 and June 2013. All HSCT re-
cipients whoweremore than 1 year post-transplantation andwhose parent/
guardian signed a informed consent document approved by the Children’s
Table 1
Characteristics of the HSCT Recipient Groups
Group 1 Group 2 Group 3 Group 4
History of acute GVHD
(grade II-IV)
No Yes Yes/no Yes/no
History of chronic GVHD No No Yes Yes
Chronic GVHD status e e Active Resolved
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study. After the completion of recipient enrollment, the acute and chronic
GVHD status of each recipient was rescored by an investigator (R.P.) using
the Glucksberg criteria to score acute GVHD and the National Institutes of
Health consensus criteria to grade chronic GVHD [10,11]. The investigator
was blinded to the results of immunologic testing at the time of the
rescoring. Ultimately, only recipients who underwent transplantation at
Children’s Hospital Los Angeles, who had received only 1 transplant, and
who had received myeloablative conditioning (except for patients with
severe aplastic anemia) were included. Thus, patients with severe combined
immune deﬁciency, who did not receive myeloablative conditioning, were
excluded.
Each patient was assigned to 1 of 4 groups: group 1, grade 0-l acute
GVHD and no history of clinical chronic GVHD; group 2, grade ll-lV acute
GVHD and no history of clinical chronic GVHD; group 3, active clinical
chronic GVHD or a history of chronic GVHD but no clinical chronic GVHD and
receiving 2 or more systemic immunosuppressive drugs; or group 4, history
of chronic GVHD but no signs of clinical chronic GVHD and off of all
immunosuppressant therapy or receivingminimal doses of a single systemic
immunosuppressive drug (Table 1). The maximal clinical severity of chronicTable 2
Characteristics of the HSCT Recipients
Characteristic Group 1 (n ¼ 37) Gr
Recipient age at transplant, yr, median (range) 6 (0.4-18) 9.5
Donor age at transplantation, yr, median (range)
* 12 (1-52) 20
y 11 (0-52) 18
Diagnosis
Malignant 15 3
Nonmalignant 22 1
HLA and donor type
Histocompatible, related 25 2
Other 12 2
HSC source
BM 33 3
CB 2 1
PBSC 2
TBI in conditioning regimen
None 25 3
450 Gy 5
>450 Gy 7 1
Serotherapy in conditioning regimen
None 8 2
ATG 19 1
Alemtuzumab 10 1
Intensity of conditioning
Nonmyeloablative 8 1
Myeloablative 29 3
Previous acute GVHD (grade II-IV)
Yes 0 4
No 37 0
Recipient sex
Male 16 1
Female 21 3
Donorerecipient sex combination
Female/male 6 1
Female/female 12 1
Male/male 9 0
Male/female 10 2
Time to evaluation, months, median (range) 67.9 (12-208) 35
Severity of chronic GVHD
Mild e e
Moderate e e
Severe e e
BM indicates bone marrow; CB, cord blood; PBSC, peripheral blood stem cells; AT
* Cord blood donors excluded.
y Cord blood donors included, and age given as 0.GVHD was scored. If more than 1 immunologic evaluation was performed,
the results from the ﬁrst complete evaluation were used.
Normal pediatric bone marrow transplant donors whose parent/
guardian provided signed informed consent served as controls.
Immunophenotypic Analyses
Human peripheral blood was collected in heparin, and mononuclear
cells were isolated on Ficoll-Hypaque gradients and cryopreserved. Thawed
mononuclear cells were stained with anti-CD4 (FITC; BD Pharmingen, San
Diego, CA), anti-CD127 (Alexa Fluor 647; BD Pharmingen), anti-CD25 (PE
Cy7; BD Pharmingen), CD45RA (PE Cy5; BD Pharmingen), and anti-FoxP3
(PE, clone 236A/E7; e-Bioscience; San Diego, CA) antibodies. Intracellular
antigen detection was performed on cells ﬁxed and permeablized with
Cytoﬁx/Cytoperm (e-Bioscience). CD4 T lymphocytes, conventional T lym-
phocytes (Tcons; CD4þ, CD127þ, CD25), and rTregs (CD4þ, CD127, CD25þ)
were quantiﬁed.
Functional Treg subpopulationsdresting Tregs (rTregs; CD4þ, CD127,
CD25þ, CD45RAþ, FoxP3þ) and aTregs (CD4þ, CD127, CD25þ, CD45RA,
FoxP3þþþ)dwere identiﬁed using a sequential gating strategy: FCS/
CD4/CD127/CD25/CD45RA/FoxP3 (Figure 1A) [7]. rTregs (Figure 1A, III,
P12) were deﬁned as CD45RAþ cells with FoxP3 staining >99.9% of the
isotype control. aTregs (Figure 1A, III, P9) were deﬁned as CD45RA cells
with FoxP3 staining >99.9% of the FoxP3 staining of the rTregs. Treg sub-
populations were measured as a percentage of CD4 T lymphocytes or total
Tregs and as lymphocytes/mL. Functional analyses of the Treg lymphocyte
subpopulations were not performed because ﬁxation was required for the
FoxP3 staining. RTEs were identiﬁed as CD4þ, CD45RAþ, CD31þ T lympho-
cytes using anti-CD31 antibody (V450; e-Bioscience) (Figure 1B). RTEs were
measured as percentage of the CD4 T lymphocyte subpopulations or asoup 2 (n ¼ 4) Group 3 (n ¼ 16) Group 4 (n ¼ 14) P Value
(4-15) 6 (0.67-16) 7 (0.4-15) .20
.68*
(17-27) 10 (1-59) 29 (1-48)
.5 (0-27) 3.5 (0-59) 2.0 (0-48)
.47
8 8
8 6
.03
9 3
7 11
.17
13 9
3 5
.63
11 8
2 1
3 5
.35
6 1
8 11
2 2
.82
2 2
14 12
<.0001
10 6
6 8
.87
7 5
9 9
.57
7 3
2 4
3 3
4 4
.3 (12-66) 73.6 (12-170) 86.7 (13-154) .20
.71
9 7
4 6
3 1
G, anti-thymocyte globulin.
Table 3
Clinical Characteristics of Recipients with Active (Group 3) or Resolved
(Group 4) Chronic GVHD
Number Organ Involvement Time to Evaluation, mo
Skin GI Lung Liver
Group 3 16 15 5 2 1 73.6
Group 4 14 13 6 0 2 86.7
GI indicates gastrointestinal tract.
Table 4
Immunosuppression of Recipients with Active (Group 3) or Resolved
(Group 4) Chronic GVHD
Immunosuppression
T/S/C Steroids Daclizumab Azathioprine
Group 3, previous
therapy
13 9 2 3
Group 3, therapy
at evaluation
12 8 e 3
Group 4, previous
therapy
13 6 6 6
T/S/C indicates tacrolimus/sirolimus/cyclosporine.
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system (BD Biosciences, San Jose, CA) and analyzed with BD FACSDiva
software.
Statistical analyses of the FACS results were performed using the Mann-
Whitney U test. Prism version 6 (Graph Pad Systems, San Diego, CA) was
used for statistical analyses (Fisher’s exact, chi-square, ANOVA, Mann-
Whitney, and linear regression analyses) and graphic generation.
RESULTS
Patient Characteristics
Eighty-nine pediatric HSCT recipients were initially
entered into the study, which resulted in 71 evaluable sub-
jects. The 18 recipients who were not included included 5
who did not undergo transplantation at Children’s Hospital
Los Angeles, 3 who had received 2 transplants, 5 who had
severe combined immune deﬁciency and did not receive
myeloablative conditioning, and 5 who did not have
adequate immune evaluation data.
The shortest time to immune evaluation was 12 months
and the longest was 208 months, with a mean of 83 months.
Of the 71 evaluable recipients, 37 were in group 1 (no history
of either acute GVHD grade ll-lV or chronic GVHD), 4 were in
group 2 (only acute GVHD grade II-IV, with no history of
clinical chronic GVHD), 16 were in group 3 (active chronic
GVHD), and 14 were in group 4 (resolved chronic GVHD)
(Table 1). No signiﬁcant differences among the 4 groups were
identiﬁed in terms of malignant/nonmalignant diseases,
recipient sex, donorerecipient sex match, recipient age at
transplantation, donor age, interval from transplantation to
immune evaluation, or the use of TBI- or serotherapy- con-
taining regimens (Table 2). The groups differed only in the
presence of acute GVHD (P < .0001) and the frequency of
related histocompatible donors (P ¼ .03). Twenty recipients
had grade ll-lV acute GVHD, with no clinical characteristics
predicting the development of acute GVHD, including degree
of histocompatibility and hematopoietic stem cells source
(data not shown). Thirty recipients had a history of clinical
chronic GVHD. The presence of grade ll-lV acute GVHD
(P ¼ .001) and the use of nonhistocompatible related donors
(P ¼ .002) were predictive of the development of clinical
chronic GVHD. All other clinical variables, including stem cell
source, were not signiﬁcantly associated with the develop-
ment of clinical chronic GVHD. Of the 14 recipients with
resolved chronic GVHD, 10 were off of all immunosuppres-
sive therapy for a mean duration of 29 months, 3 were
receiving minimal doses of a single systemic immunosup-
pressive drug (ie, 0.1 mg of tacrolimus every day, 1 mg of
prednisone every other day, and 2 mg of prednisone every
other day), and 1 recipient with Addison disease was
receiving 15 mg of hydrocortisone daily.
No clinical differences were identiﬁed between the re-
cipients with active chronic GVHD (group 3) and those with
resolved chronic GVHD (group 4), including interval between
HSCT and immune evaluation, organs involved, time to
clinical onset of chronic GVHD, and immunosuppressive
therapy received currently (group 3) or previously (group 4)
(Tables 3 and 4). Thus, no differences in the clinical charac-
teristics of the recipients with active chronic GVHD and those
with resolved chronic GVHD could be identiﬁed.
Assessment of T Lymphocytes
We analyzed the pediatric HSCT recipients for the fre-
quency of CD4 T lymphocytes, Tcons, and Tregs (CD4þ,
CD127, CD25þ). No differences among the GVHD groups
were identiﬁed (Figure 2A). In addition, there were no dif-
ferences in the absolute number of CD4 T lymphocytes(Figure 2B). The Miyara classiﬁcation scheme permits the
immunophenotypic identiﬁcation of the functional Treg
subpopulations, including rTregs (CD4þ, CD127, CD25þ,
CD45RAþ, FoxP3þ; P12) and their progeny, aTregs (CD4þ,
CD127, CD25þ, CD45RA, FoxP3þþþ; P9) [7]. Regulatory
function is associated only with the rTreg and aTreg sub-
populations, and not with the other FoxP3-expressing sub-
population or the FoxP3-negative subpopulation (Figure 1A).
The HSCT recipients were assessed for frequency of rTregs
as percentages of both CD4 T lymphocytes and Tregs
(Figure 3A). The frequency of rTregs in group 3 recipients was
decreased, whereas the frequency in group 1 and group 4
recipients was similar to that in normal pediatric donors. The
frequency of rTregs in the group 3 recipients was lower than
that of normal donors (P ¼ .009), group 1 recipients
(P ¼ .001), and group 4 recipients (P ¼ .005). Analysis of the
absolute numbers of rTregs (rTregs/mL) demonstrated almost
identical results (Figure 3A). When only the group 4 re-
cipients who were off of all immunosuppression were
analyzed, the frequency of rTregs in the group 3 recipients
still differed from that of the group 4 recipients (P ¼ .01).
Assessment of the frequency of aTregs revealed elevated
frequencies in the group 1 and 4 recipients compared with
normal pediatric donors, but a normal frequency in the
group 3 recipients with active chronic GVHD (Figure 3B).Thymic Function
In the present study, we found normal frequencies and
numbers of rTregs in pediatric HSCT recipients with resolved
chronic GVHD (group 4), but decreased frequencies and
numbers in recipients with active chronic GVHD (group 3).
The increased thymic production of rTregs may be a possible
mechanism for the normalization of rTregs in the HSCT re-
cipients with resolved chronic GVHD. To directly determine
the status of thymic function in the HSCT recipients, we
evaluated the frequencies of RTEs (CD4þ, CD45RAþ, CD31þ)
in total CD4 T lymphocytes, Tcons, and Tregs. We found an
increased frequency of RTEs in the total CD4 T lymphocytes
of the group 1 recipients compared with normal donors
(P ¼ .009), but not in any of the other groups (Figure 4A).
There was no signiﬁcant difference in the frequency of RTEs
in Tcons or Tregs comparedwith normal donors in any group.
Figure 2. (A) Determination of the frequency of CD4 T lymphocytes, Tcons, and Tregs in group 1, 2, 3, and 4 recipients and normal pediatric donors (D). Results are
presented as percentage of total lymphocytes (CD4) or of CD4 T lymphocytes (Tcons and Tregs). (B) Determination of the absolute number of CD4 T lymphocytes
(cells/mL) in group 1, 2, 3, and 4 recipients and normal pediatric donors (D).
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we directly determined the RTE content of the rTregs
(Figures 1A and 4B). The frequency and absolute number of
RTEs in the rTreg subpopulation of the group 3 recipients
with active chronic GVHD was reduced compared with
normal donors (P ¼ .01), with group 1 recipients with no
history of acute or chronic GVHD (P¼ .005), and with group 4
recipients with resolved chronic GVHD (P ¼ .05). The per-
centage of RTEs within the rTregs was the same for all groups
and the normal donors (Figure 4B).
To determine whether the decrease in the frequency and
number of RTE within the rTreg subpopulation was speciﬁc
to the rTregs or was related to a general decrease in thymic
function, we evaluated the frequency of RTEs in the CD45RAþ
Treg subpopulation, which does not express FoxP3 (sub-
population A), as a speciﬁcity control (Figures 1A and 4C).Figure 3. (A) Determination of the frequency of rTregs in group 1, 2, 3, and 4 recipien
Tregs, and determination of the absolute number of rTregs in group 1, 2, 3, and 4 reci
frequency of aTregs in group 1, 2, 3, and 4 recipients and normal donors (D), presenThe frequency and number of RTEs in subpopulation A T
lymphocytes did not differ among the 4 recipients groups
and the normal donors, demonstrating that the decreased
RTEs in the rTregs of recipients with active chronic GVHD
(group 3) was limited to their rTregs.
We performed linear regression analyses of the fre-
quencies of rTregs and their RTEs to evaluate the impact, if
any, of the interval after HSCT on immune evaluations. The
frequency of rTregs remained stable over time in both the
group 1 and group 3 recipients, although the group 3 re-
cipients had consistently lower frequencies (Figure 5A). The
group 4 recipients with resolved chronic GVHD had initially
elevated rTreg frequencies that decreased over time (P¼ .02).
Analyses of RTE frequencies demonstrated stable RTE pro-
duction in group 1 and 3 recipients over the 12 to 17 year
span studied, whereas the group 4 recipients exhibited ats and normal donors (D), presented as percentages of CD4 T lymphocytes and
pients and normal donors (D), presented as rTregs/mL. (B) Determination of the
ted as percentages of CD4 T lymphocytes and Tregs.
Figure 4. (A) Determination of the frequency of RTEs (CD4þ, CD45RAþ, CD31þ) in CD4 T lymphocytes, Tcons, and Tregs in group 1, 2, 3, and 4 recipients and normal
donors (D). Results are presented as percentage of RTEs in the total population. (B) RTE frequency, absolute number, and percentage of rTregs in group 1, 2, 3, and 4
recipients and normal donors (D). Results are presented as percentage of CD4 T lymphocytes, RTEs/mL, and percentage of rTregs. (C) Frequency and absolute
numbers of RTEs in the subpopulation A T lymphocytes of group 1, 2, 3, and 4 recipients and normal donors (D). Results are presented as percentage of CD4 T
lymphocytes and RTEs/mL.
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(Figure 5B).
DISCUSSION
In our cross-sectional analysis of the role of Tregs in the
pathogenesis of chronic GVHD and its clinical resolution in
pediatric HSCT recipients, we did not identify any differences
in the frequency of immunophenotypic Tregs (CD4þ, CD127,Figure 5. (A) Linear regression analysis of the frequency of rTregs versus time (in mon
the frequency of RTEs in rTregs versus time (in months) from HSCT in group 1, 3, anCD25þ) in recipients with or without acute and/or chronic
GVHD. However, when using the Miyara classiﬁcation
scheme to focus on the functional Treg subpopulations
(rTregs and aTregs), we identiﬁed decreases in the frequency
and number of rTregs in recipientswith active clinical chronic
(group 3). The frequencies and number of rTregs in recipients
who had had resolution of their chronic GVHD (group 4) or
who had no history of either acute or chronic GVHD (group 1)ths) from HSCT in group 1, 3, and 4 recipients. (B) Linear regression analysis of
d 4 recipients.
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donors, suggesting that the normalization of rTregs was
correlated with the clinical resolution of their chronic GVHD.
HSCT recipients with active chronic GVHD (group 3) and
resolved chronic GVHD (group 4) did not differ in any clinical
characteristics, including the frequency of previous acute
GVHD, use of TBI- or serology-containing preparatory regi-
mens, recipient or donor age, stem cell source,
donorerecipient histocompatibility, frequency of fema-
le/male donorerecipient pairs, or severity of chronic
GVHD. Most importantly, the mean interval from HSCT to
immune evaluation did not differ. Previous studies in adult
HSCT recipients demonstrated that 50% of recipients with a
history of chronic GVHD were completely off immunosup-
pressive therapy at 7 years [8,9]. Thus, if the recipients with
resolved chronic GVHD (group 4) were signiﬁcantly longer
out from HSCT compared with recipients with active chronic
GVHD (group 3), then the greater time fromHSCTmight have
contributed to their clinical resolution.
The sole identiﬁed difference between the HSCT re-
cipients with active chronic GVHD (group 3) and resolved
chronic GVHD (group 4) was the decrease in rTregs in those
with active chronic GVHD. The presence of normal fre-
quencies and number of rTregs in recipients with resolved
chronic GVHD is consistent with the results of clinical trials
with IL-2 in adult HSCT recipients with therapy-resistant
chronic GVHD, who demonstrated increased Tregs and clin-
ical improvement [12,13]; however, those adult studies did
not assess the affect of IL-2 therapy on the functional Treg
subpopulations, either rTregs or aTregs.
Recent studies in murine models of GVHD have demon-
strated that acute GVHD results in a marked decrease (>90%)
in the frequency of AIRE-expressing (AIREþ) medullary
thymic epithelial cells (mTECs) and that the expression of
autologous tissue-speciﬁc antigens (TSA) is limited in the
residual mTECs [14,15] The reduction in TSA expression was
greatest in organs that are the targets of chronic GVHD (eg,
gastrointestinal tract, skin, liver). Thus, the reduction in
AIREþ mTECs after acute GVHD can result in both decreased
Treg production and the peripheral presence of autoreactive
T lymphocytes with potential speciﬁcity for chronic GVHD
target organs owing to the limited TSA expression and
decreased negative thymic selection. Furthermore, following
murine acute GVHD, donor-derived T lymphocytes with
speciﬁcity for shared donor- and recipient-associated anti-
gens have been identiﬁed. Potential nonpolymorphic target
antigens include TSA, MHC class II determinants, and envi-
ronmental pathogens [16-19]. Thus, chronic GVHD may be
related to the peripheral presence of donor-derived autor-
eactive T lymphocytes in the context of immune dysregula-
tion (ie, an inadequate number of functional Tregs).
Given that previous clinical evaluations have identiﬁed
persistent defects in thymic function in HSCT recipients with
a history of chronic GVHD, the basis for the normalization of
rTregs in the recipients with resolved chronic GVHD was not
clear [20,21]. A decreased frequency of apoptotic Tregs was
one possibility [22]. Another possibility was that thymic
function improved in some recipients with active chronic
GVHD, resulting in the production of adequate numbers of
rTregs to support normal immune regulation.
Thus, we evaluated the frequency of RTEs (CD4þ,
CD45RAþ, CD31þ) in the CD4 T lymphocytes, total Tregs, and
the rTreg subpopulation. The frequency of RTEs in the total
Tregs was the same in all groups (Figure 4A); however, the
frequency and number of RTEs in the rTregs was reduced inrecipients with active chronic GVHD (group 3) compared
with normal pediatric donors (P ¼ .01) and recipients with
resolved chronic GVHD (group 4; P ¼ .05) (Figure 4B). As a
speciﬁcity control, we measured the frequency and number
of RTEs in the CD45RAþ subpopulation of the Tregs that did
not express FoxP3 (subpopulation A) (Figure 1A). We found
no decrease in the frequency or number of RTEs in the sub-
population A T lymphocytes from any group, demonstrating
that the decrease in RTEs in rTregs was limited to the rTreg
subpopulation and was not secondary to a general decrease
in thymic function.
Our ﬁndings of increased/normal RTE frequency in the
rTregs of pediatric recipients with resolved GVHD is consis-
tent with the 8-fold increased frequency of RTEs found in the
total Tregs of adult chronic GVHD recipients who received
low-dose IL-2 and demonstrated clinical improvement [13].
The frequency of T cell excision circles in the total T lym-
phocytes from adult HSCT recipients (mean age, 57 years)
with resolved chronic GVHD was the same as that in age-
matched normal controls and superior to that in recipients
with active chronic GVHD, suggesting that some adult HSCT
recipients have adequate thymic reserves to support the
immunologic resolution of their chronic GVHD [23]. Thus,
the association of improved thymic functionwith the clinical
resolution of chronic GVHD is not limited to pediatric HSCT
recipients.
A signiﬁcant difference between the recipients with
active chronic GVHD (group 3) and those with resolved
chronic GVHD (group 4) is that all of the group 3 recipients
were on immunosuppressive therapy, whereas most (10 of
14) of the group 4 recipients were off of all therapy and the
other 4 recipients were on minimal therapy (Table 4). We
believe that the observed differences in the frequencies of
both RTEs and rTregs were not related to immunosuppres-
sive therapy, for several reasons: (1) There was no decrease
in the frequency or number of RTEs in the subpopulation A T
lymphocytes; (2) pediatric patients with juvenile systemic
sclerosis who were on and off immunosuppressive therapy
had similar decreases in rTregs; and (3) pediatric patients
with inﬂammatory bowel disease who were on immuno-
suppressive therapy did not have exhibit decreases in rTregs
[24 and data not shown]. There were no differences in the
frequency of rTregs between the 8 group 3 recipients who
were on systemic steroid therapy and the 8 recipients not on
systemic steroid therapy (data not shown) Thus, the decrease
in rTregs in recipients with active chronic GVHD is not
related to their concomitant immunosuppression.
The present report is the ﬁrst to identify immunologic
differences between HSCT recipients with active chronic
GVHD and those with resolved chronic GVHD. Previous
clinical trials of immunosuppressive therapy to treat chronic
GVHD did not explore the biological differences between
recipients whowere able to discontinue immunosuppressvie
therapy and those who were not. Our results support the
conclusions that the decrease in rTregs in recipients with
active chronic GVHD is related to the sustained hypo-
production of rTregs by the thymus, and that the clinical
resolution of chronic GVHD and withdrawal of immuno-
suppressive therapy require the reestablishment of normal
immune regulation secondary to the improved thymic pro-
duction of rTregs.
Debate on the pathogenesis of chronic GVHD has centered
onwhether chronic GVHD is a continuation of the pathogenic
mechanisms that cause acute GVHD (ie, donor-derived
T lymphocytes with speciﬁcity for recipient-restricted
K.M. Mahadeo et al. / Biol Blood Marrow Transplant 20 (2014) 1508e1515 1515histocompatibility antigens/cytokines) or a disease of immune
dysregulation [1-3]. The present demonstration of decreased
rTregs in HSCT recipients with active chronic GVHD is similar
to the reported deﬁciencies of rTregs in both adult and pedi-
atric patients with systemic sclerosis, indicating that immune
dysregulation may be central to the pathogenesis of both
systemic sclerosis and chronic GVHD [24,25].
The present study has several limitations, principally that
it was a cross-sectional study in pediatric patients. A longi-
tudinal study with primarily adult recipients is needed to
deﬁnitively deﬁne the relationship between changes in
rTregs and the recipients’ clinical GVHD status, as well as the
impact of immunosuppressive therapy on rTregs. The pre-
sent study was conducted in pediatric HSCT recipients, who
have superior thymic function compared with adult HSCT
recipients and are less likely to have received mobilized
peripheral blood stem cells [26,27]. If the clinical resolution
of chronic GVHD is secondary to the thymic generation of
adequate numbers of functional Tregs, then adult HSCT re-
cipients with lower thymic function might be expected to
have lower rates of the immunologic resolution of chronic
GVHD. No attempt was made to deﬁne the effector mecha-
nisms in the chronic GVHD recipients, which may differ be-
tween pediatric and adult HSCT recipients.
Murine experiments have indicated that mTECs are
generated from thymic epithelial precursors [28-30]. Thus,
HSCT recipients who have experienced decreased AIREþ
mTECs after HSCT and acute GVHD may be able to generate
new AIREþ mTECs if adequate residual TEC precursors are
present; however, HSCT recipients who have inadequate
residual mTEC precursors may have sustained thymic
dysfunction and persistent active chronic GVHD. The clinical
administration of IL-2 has produced only temporary in-
creases in Tregs. To achieve sustained improvement in the
functional Tregs, future clinical trials should explore the
improvement in thymic function after HSCT rather than
immunosuppression.ACKNOWLEDGMENTS
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